诺和诺德公司发布减肥药Amycretin早期试验结果，显示36周内体重下降24.3%，且显示出改善血糖水平的迹象。

Core Insights - Novo Nordisk has released early trial results for its weight loss drug Amycretin, indicating a weight reduction of 24.3% over 36 weeks, along with signs of improved blood sugar levels [1] Group 1 - The early trial results demonstrate significant weight loss potential with Amycretin, achieving a 24.3% reduction in body weight within 36 weeks [1] - The drug also shows promising effects on blood sugar levels, suggesting additional health benefits beyond weight loss [1]